Table 1.
Summary of included studies.
| Author | Year | Design | Inclusion period | Number of HR+/HER2− | Number of HR+/HER2+ | Number of HR−/HER2+ | Number of HR−/HER2− | Most frequently used chemotherapy regimens included | HER2 directed therapy | MRI field strenght | pCR definition | rCR definition | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anthra-cyclines | Taxanes | Other agents | Trastuzumab | Pertuzumab | |||||||||||
| Eom | 2016 | Retrospective | 2009–2010 | . | . | . | 64 | X | . | . | . | 1.5 T | ypT0/is or residual cancer <0.3 cm | NR | |
| Andrade | 2017 | NR | 2005–2012 | . | . | 40 | 32 | NR | NR | NR | NR | NR | NR | NR | NR |
| Ramshorst | 2017 | Retrospective | 2000–2016 | . | 154 | 143 | . | . | X | . | X | X | Mix | ypT0/is | Absence of enhancement |
| Iwase | 2018 | Retrospective | 2013–2016 | 53 | 45 | 44 | 36 | X | X | . | NR | NR | 3.0 T | ypT0 | Absence of enhancement |
| Marin Alcala | 2018 | NR | NR | . | . | . | 114 | X | . | . | . | . | NR | ypT0/isN0 | NR |
| Murphy | 2018 | Prospective | 2013–2015 | 10 | . | . | 14 | X | X | . | . | . | 3.0 T | ypT0/is | Disappearance of lesion(s) |
| Namura | 2018 | Retrospective | 2009–2014 | 360 | 95 | 85 | 176 | X | X | . | X | . | 3.0 T | ypT0/is | Absence of enhancement |
| Gasol Cudos | 2019 | Retrospective | NR | 145 | 88 | 64 | 119 | X | X | . | X | X | NR | ypT0/is | Absence of enhancement |
| Gampenrieder | 2019 | Retrospective | 2006–2016 | 86 | 37 | 33 | 90 | X | X | . | X | X | Mix | ypT0/isN0 | Absence of enhancement |
| Negrao | 2019 | Retrospective | 2014–2017 | 134 | 55 | 31 | 90 | NR | NR | NR | NR | NR | 1.5 T | ypT0/is | Absence of enhancement |
| Zhang, X | 2020 | Retrospective | 2015–2018 | 11 | . | 31 | 27 | X | X | . | X | . | 1.5 T | ypT0 | Absence of enhancement |
| De Los Santos | 2011 | Retrospective | 2002–2009 | 33 | 12 | 11 | 25 | X | X | . | X | . | 1.5 T | ypT0/is | Absence of mass or enhancement |
| De Los Santos | 2013 | Retrospective | 2002–2011 | 327 | 148 | 101 | 155 | X | X | . | X | . | NR | ypT0 | Absence of mass or enhancement |
| Hayashi | 2013 | Retrospective | 2003–2008 | 93 | 54 | 66 | 44 | NR | NR | NR | NR | NR | 1.5 T | ypT0/is | Absence of enhancement |
| Sabadell | 2014 | Retrospective | 2006–2012 | . | . | . | 28 | NR | NR | NR | . | . | NR | ypT0/is | Disappearance of lesion(s) |
| Kim | 2015 | Retrospective | 2009–2012 | . | . | . | 35 | X | X | . | . | . | 3.0 T | ypT0/is | Absence of enhancement |
| Fukuda | 2016 | Retrospective | 2005–2007 | 161 | 24 | 32 | 44 | X | X | . | . | . | 1.5 T | ypT0/is | Absence of mass or enhancement |
| Schaefgen | 2016 | Retrospective | 2006–2011 | 61 | . | . | 39 | X | X | . | . | . | 1.5 T | ypT0 | Disappearance of lesion(s) |
| Bufi | 2014 | Retrospective | 2007–2012 | 143 | 28 | 17 | 37 | X | X | . | NR | NR | 1.5 T | ypT0 | Absence of enhancement |
| Santamaria | 2019 | Retrospective | 2015–2017 | 42 | 10 | 18 | 12 | X | X | . | 1.5 T | ypT0/is | Absence of enhancement | ||
| Zhang, K | 2020 | Retrospective | 2013–2018 | 400 | 197 | 222 | 212 | X | X | X | X | . | 1.5 T | ypT0/is | Absence of enhancement |
| Pasquero | 2020 | Retrospective | 2015–2017 | . | . | . | 13 | X | X | . | . | . | Mix | NR | NR |
| Graeser | 2021 | Prospective | 2012–2015 | . | 103 | 50 | 91 | . | . | X | X | X | Mix | ypT0/isN0 | Absence of enhancement |
| Nakashima | 2021 | Retrospective | 2014–2017 | 117 | 28 | 42 | 89 | X | X | . | X | . | 3.0 T | ypT0 | Absence of enhancement |
| Palshof | 2021 | Retrospective | 2016–2019 | 52 | 47 | 22 | 30 | X | X | . | X | . | 1.5 T | ypT0 | Absence of enhancement |
| Winder | 2021 | Retrospective | 2013–2018 | 45 | 31 | 16 | 42 | X | X | . | X | . | 3.0 T | ypT0 | Absence of enhancement in breast and axilla |
NR not reported.